ADVM insider transaction filings
Adverum Biotechnologies, Inc. — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-12-10. Screen ADVM transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-10 | 4 | Seyedkazemi Setareh — CHIEF DEVELOPMENT OFFICER | Code (U): 54,874 · Code (U): 8,125 · Grant/award (A): 85,000 @ $0 · Code (U): 88,332 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 42,500 (derivative) · +4 more | EDGAR |
| 2025-12-10 | 4 | Kiss Szilard — Director | Disposition to issuer (D): 1,250 (derivative) · Disposition to issuer (D): 2,000 (derivative) · Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 2,500 (derivative) · Disposition to issuer (D): 2,500 (derivative) · +2 more | EDGAR |
| 2025-12-10 | 4 | Hong Soo — Director | Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · Disposition to issuer (D): 10,450 (derivative) | EDGAR |
| 2025-12-10 | 4 | Ozden Rabia Gurses — Chief Medical Officer | Code (U): 8,125 · Grant/award (A): 85,000 @ $0 · Code (U): 85,000 · Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 85,000 (derivative) · +2 more | EDGAR |
| 2025-12-10 | 4 | Lupher, Jr. Mark L. — Director | Code (U): 13,000 · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · +3 more | EDGAR |
| 2025-12-10 | 4 | Soparkar Peter — CHIEF OPERATING OFFICER | Code (U): 80,189 · Code (U): 13,125 · Grant/award (A): 150,000 @ $0 · Code (U): 157,333 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 64,394 (derivative) · +8 more | EDGAR |
| 2025-12-10 | 4 | Nicholson, C. David — Director | Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · Disposition to issuer (D): 10,450 (derivative) | EDGAR |
| 2025-12-10 | 4 | Svoronos Dawn — Director | Code (U): 5,000 · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · +1 more | EDGAR |
| 2025-12-10 | 4 | Tuckson Reed Vaughn — Director | Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · Disposition to issuer (D): 10,450 (derivative) | EDGAR |
| 2025-12-10 | 4 | Fischer Laurent — CEO, PRESIDENT AND DIRECTOR, Director | Option exercise (M): 150,000 @ $4.20 · Code (U): 351,513 · Code (U): 25,000 · Grant/award (A): 500,000 @ $0 · Code (U): 522,666 · Disposition to issuer (D): 93,000 (derivative) · +10 more | EDGAR |
| 2025-12-10 | 4 | Scopa James Paul — Director | Code (U): 10,333 · Disposition to issuer (D): 4,666 (derivative) · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · +3 more | EDGAR |
| 2025-12-10 | 4 | Rubinstein Linda M — CHIEF FINANCIAL OFFICER | Option exercise (M): 48,750 @ $4.20 · Code (U): 61,150 · Code (U): 8,125 · Grant/award (A): 42,000 @ $0 · Code (U): 42,000 · Disposition to issuer (D): 35,000 (derivative) · +3 more | EDGAR |
| 2025-12-10 | 4 | Machado Patrick — Director | Code (U): 8,818 · Disposition to issuer (D): 1,000 (derivative) · Disposition to issuer (D): 6,476 (derivative) · Disposition to issuer (D): 3,360 (derivative) · Disposition to issuer (D): 3,500 (derivative) · Disposition to issuer (D): 4,500 (derivative) · +7 more | EDGAR |
| 2025-12-10 | 4 | Whitcup Scott M — Director | Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · +1 more | EDGAR |
| 2025-12-09 | 4 | Frazier Life Sciences Public Fund, L.P. — 10% owner FHMLSP, L.P. — 10% owner FHMLSP, L.L.C. — 10% owner | Code (U): 4,288,949 @ $3.56 | EDGAR |
| 2025-12-08 | 4 | Soparkar Peter — CHIEF OPERATING OFFICER | Purchase (P): 50,000 @ $4.22 | EDGAR |
| 2025-12-08 | 4 | Fischer Laurent — CEO, PRESIDENT AND DIRECTOR, Director | Purchase (P): 11,085 @ $4.24 · Purchase (P): 117,614 @ $4.31 | EDGAR |
| 2025-12-05 | 4 | Leonard Braden Michael — 10% owner | Sale (S): 524,560 @ $4.19 | EDGAR |
| 2025-12-03 | 4 | Leonard Braden Michael — 10% owner | Sale (S): 300,000 @ $4.20 · Sale (S): 51,961 @ $4.20 · Sale (S): 222,925 @ $4.17 | EDGAR |
| 2025-06-20 | 4 | Soparkar Peter — CHIEF OPERATING OFFICER | Disposition to issuer (D): 40,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 · Disposition to issuer (D): 4,074 (derivative) @ $0 · Grant/award (A): 4,074 (derivative) @ $0 · Disposition to issuer (D): 13,999 (derivative) @ $0 · Grant/award (A): 13,999 (derivative) @ $0 · +12 more | EDGAR |
| 2025-06-20 | 4 | Seyedkazemi Setareh — CHIEF DEVELOPMENT OFFICER | Disposition to issuer (D): 42,500 (derivative) @ $0 · Grant/award (A): 42,500 (derivative) @ $0 · Disposition to issuer (D): 8,500 (derivative) @ $0 · Grant/award (A): 8,500 (derivative) @ $0 · Disposition to issuer (D): 40,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Ozden Rabia Gurses — Chief Medical Officer | Disposition to issuer (D): 8,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 · Disposition to issuer (D): 4,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Kiss Szilard — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Tuckson Reed Vaughn — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Svoronos Dawn — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Lupher, Jr. Mark L. — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Hong Soo — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Nicholson, C. David — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Fischer Laurent — CEO, PRESIDENT AND DIRECTOR, Director | Disposition to issuer (D): 120,000 (derivative) @ $0 · Grant/award (A): 120,000 (derivative) @ $0 · Disposition to issuer (D): 68,000 (derivative) @ $0 · Grant/award (A): 68,000 (derivative) @ $0 · Disposition to issuer (D): 45,499 (derivative) @ $0 · Grant/award (A): 45,499 (derivative) @ $0 · +10 more | EDGAR |
| 2025-06-20 | 4 | Scopa James Paul — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Rubinstein Linda M — CHIEF FINANCIAL OFFICER | Disposition to issuer (D): 85,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 · Disposition to issuer (D): 35,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Machado Patrick — Director | Grant/award (A): 10,450 (derivative) @ $0 · Grant/award (A): 3,140 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Whitcup Scott M — Director | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Soparkar Peter — CHIEF OPERATING OFFICER | Sale (S): 2,960 @ $2 | EDGAR |
| 2025-05-16 | 4 | Seyedkazemi Setareh — CHIEF DEVELOPMENT OFFICER | Sale (S): 924 @ $2 | EDGAR |
| 2025-05-16 | 4 | Fischer Laurent — CEO, PRESIDENT AND DIRECTOR, Director | Sale (S): 9,126 @ $2 | EDGAR |
| 2025-04-28 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 20,407 @ $5.04 · Purchase (P): 16,593 @ $5.19 | EDGAR |
| 2025-04-28 | 4/A | Leonard Braden Michael — 10% owner | Purchase (P): 20,407 @ $5.04 · Purchase (P): 16,593 @ $5.19 | EDGAR |
| 2025-04-24 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 300,000 @ $3 · Purchase (P): 50,000 @ $2.98 | EDGAR |
| 2025-04-02 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 19,566 @ $4.38 · Purchase (P): 15,209 @ $4.04 | EDGAR |
| 2025-03-27 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 20,407 @ $5.04 · Purchase (P): 16,593 @ $5.19 | EDGAR |
| 2025-03-20 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 18,000 @ $4.60 · Purchase (P): 44,341 @ $4.73 · Purchase (P): 25,000 @ $4.94 · Purchase (P): 30,600 @ $5.61 | EDGAR |
| 2025-02-28 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 164,886 @ $4.01 · Purchase (P): 86,802 @ $4.46 · Purchase (P): 85,068 @ $4.60 | EDGAR |
| 2025-02-27 | 4 | Soparkar Peter — CHIEF OPERATING OFFICER | Grant/award (A): 13,125 @ $0 · Grant/award (A): 78,750 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Seyedkazemi Setareh — CHIEF DEVELOPMENT OFFICER | Grant/award (A): 8,125 @ $0 · Grant/award (A): 48,750 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Ozden Rabia Gurses — Chief Medical Officer | Grant/award (A): 8,125 @ $0 · Grant/award (A): 48,750 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Fischer Laurent — CEO, PRESIDENT AND DIRECTOR, Director | Grant/award (A): 25,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Rubinstein Linda M — CHIEF FINANCIAL OFFICER | Grant/award (A): 8,125 @ $0 · Grant/award (A): 48,750 (derivative) @ $0 | EDGAR |
Recent 8-K events — Adverum Biotechnologies, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-12-09 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-21 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-31 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADVM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →